Zymeworks Inc. 8K

Zymeworks Inc. filed an 8-K to report Q2 2026 results and a corporate update including the upcoming zanidatamab PDUFA decision, the expected 2H 2026 closing of its Theravance Biopharma acquisition, and ongoing execution of its share repurchase and financing strategy amid a shift to a diversified, revenue-generating business model.

On August 6, 2026, Zymeworks Inc. reported its second quarter 2026 financial results and provided a corporate update highlighting the upcoming August 25, 2026 U.S. PDUFA target action date for zanidatamab, which could trigger a $250 million U.S. approval milestone and up to $190 million in additional global regulatory milestones, progress across its partnered and wholly owned R&D programs, and the expected second-half 2026 closing of its previously announced acquisition of Theravance Biopharma, Inc., which is anticipated to be earnings accretive and add durable commercial cash flows including YUPELRI profit share and other royalty interests. The company also detailed its capital allocation actions and balance sheet, including a $322.5 million cash and securities position as of June 30, 2026, utilization of $49.4 million under a new $125 million 2026 share repurchase program (and $213.6 million cumulatively since 2024), a royalty-backed note financing with Royalty Pharma that contributed to higher interest expense, and its decision to discontinue providing cash runway guidance as it transitions to a diversified, revenue-generating business model. Financially, Zymeworks generated $4.6 million in revenue, incurred $27.4 million of R&D expense and $19.3 million of G&A expense, and reported a net loss of $45.0 million for the quarter, versus net income of $2.3 million in the prior-year period, primarily due to the absence of large one-time collaboration milestones and new interest expense on the royalty-backed note, partially offset by lower operating expenses.

Filing Facts

CIK

1937653

Ticker

ZYME

Form

8K

Source Type

fda

Accession

0001937653-26-000046

Alert Tier

7